Artesunate/pyronaridine

Artesunate/pyronaridine, sold under the brand name Pyramax, is a fixed dose combination medication for the treatment of malaria.[3][1] It can be used for malaria of both the P. falciparum and P. vivax types.[1] It combines artesunate and pyronaridine.[3] It is taken by mouth.[2]

Artesunate/pyronaridine
Combination of
ArtesunateAntimalarial
PyronaridineAntimalarial
Clinical data
Trade namesPyramax[1]
Other namesArtesunate/pyronaridine tetraphosphate[1]
Routes of
administration		By mouth[2]
ATC code

The combination is generally well tolerated.[1] Side effects may include headache, vomiting, or cough.[1] Use in those with severe liver disease or kidney disease is not recommended.[2] Use is not generally recommended in early pregnancy.[2] However, there are no other options and if treatment may save the mother's life it may be used.[2] The two components work by different mechanisms.[2]

It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.[3] In 2010 the wholesale cost of a course of treatment in the developing world was between 0.55 and 2.18 USD.[1]

Medical uses

Artesunate/pyronaridine is used for malaria of both the P. falciparum and P. vivax types.[1] It is not recommended for severe disease.[2]

A 2019 review found that the combination compared well to artemether/lumefantrine.[4] Benefits also appear similar to mefloquine together with artesunate.[4] It is not recommended for the prevention of malaria.[2]

References
  1. "Application for inclusion in the WHO Model List of essential medicines" (PDF). WHO. Nov 2010. Retrieved 29 June 2017.
  2. "Pyramax 180 mg/60 mg Film-coated tablet" (PDF). EMA. Retrieved 13 December 2017.
  3. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. Pryce J, Hine P (January 2019). "Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria". The Cochrane Database of Systematic Reviews. 1: CD006404. doi:10.1002/14651858.CD006404.pub3. PMC 6353203. PMID 30620055.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.